Lexeo Reports Q3 Loss and GAAP EPS Miss

Lexeo Therapeutics reported Q3 2026 GAAP EPS of -$0.43, missing estimates by $0.10. The company posted a $38.3M net loss, up 88.8% YoY, with no revenue. Lexeo said its cash, cash equivalents and investments totaled $219.1 million and should fund operations into 2028.

The EPS shortfall marks weaker-than-expected quarterly performance for Lexeo. The company expects its available liquidity to support operations into 2028, extending the current funding horizon.

  • 1Q3 2026 GAAP EPS was -$0.43, $0.10 below estimates.
  • 2Lexeo reported a $38.3M net loss in Q3 2026, an 88.8% YoY increase, with no revenue.
  • 3Cash, cash equivalents and investments totaled $219.1 million, which the company expects to fund operations into 2028.
  • 4The Mantle acquisition contributed to higher costs and added Friedreich ataxia assets, according to the company.

Sources